300142.SZ
沃森生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.90
−7.45%Aug 28, 2026, 09:51 UTC
Walvax Biotechnology announced its first-half 2026 results: net profit attributable to shareholders was 54.1922 million yuan, up 25.56% year-on-year.
Source:Aug 27, 2026, 12:13 UTC
Walvax Biotechnology announced that its 2026 private placement of shares to specific targets has been accepted for review by the Shenzhen Stock Exchange.
Source:Aug 15, 2026, 12:18 UTC
China Haisum Engineering Co., Ltd. won the bid for the energy and carbon management platform project of Yunnan Walvax Biotechnology Co., Ltd.
Source:Aug 3, 2026, 12:08 UTC
Walvax Biotechnology plans to issue no more than 208 million A-shares to specific investor Tengyun Xinwo, with subscription amount not exceeding 2.203 billion yuan, to supplement working capital; after the issuance, Tengyun Xinwo will become the controlling shareholder and Huang Tao the actual controller.
Source:Jul 23, 2026, 11:13 UTC
Watson Bio's subsidiary Yuxi Zerun Biotechnology received a drug registration certificate from the Tanzania Medicines and Medical Devices Authority for its bivalent HPV vaccine WALRINVAX, granting marketing authorization in Tanzania.
Source: